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Breast cancer is the leading cancer among women in Malaysia. Genetics, 
experimental and epidemiological data suggest that breast cancer develops from 
complex interaction between inherited susceptibility and environmental factors. 
Accumulating evidence suggests that the PI3WAkt signaling pathways play a 
causative role in tumorigenesis of breast cancer. 
By employing the immunohistochemical method, the expression of several key 
regulators or related biomolecules of the PI3WAkt signaling pathways in 43 archived 
formalin fixed, paraffin embedded tissues of surgically resected breast carcinoma 
specimens from 1999 to 2002, were studied. A hnctional assay was performed to 
determine the expression of Akt related molecules when treated with SDF-la 
recombinant protein. 
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The results showed that: 1) The expression rates in tumour tissue of ERa, ERP, c- 
erbB2, p-~ktm08,  p- p - ~ ~ ~ S 1 3 6 ,  SDF-1 and Ki67 were 25.6%, 4.7%, 5 1.2%, 
81.4%, 48.8%, 67.4%, 93.0% and 26.8%, respectively. In contrast, in the apparently 
normal adjacent tissue, the expression rates of these molecules were 23.1%, 53.8%, 
0%, 7.7%, 7.7%, 53.8%, 92.3% and 15.4%, respectively. 2) Correlation of 
biomolecules with tumour tissues and apparently normal adjacent tissues was seen in 
the following biomolecules: ERP (p=0.001), c-erbB2 (p<0.001), p-~ktT308 (p=<0.001) 
and Ki67 (p=<0.001). 3) In tumour tissue, significant correlation was found between 
ERP with p - ~ ~ ~  (p=0.004), p - ~ k t  S473 with p-BAD (p=0.006), c-erbB2 with 
p-Akt and Ki67 (p=0.014 and p=0.000 respectively) and c-erbB2 with SDF-1 
(p=0.047). In the apparently normal adjacent tissue, a significant correlation was 
found between ERa with p - ~ ~ ~ S ' 3 6  (p=0.042), ERP with p-Akt S473 and p-BAD 
(p=0.009 and p=O.OOl respectively), and c-erbB2 with p - ~ k t  T308 (p=0.042). 
Our study also showed that SDF-la protein had a different effect on the expression 
of biomolecules, namely p-AktT308, p- AktS473 and p - ~ ~ ~ S ' 3 6 .  In this hnctional assay, 
we found that SDF-la could possible induce cell survival by inducing 
phosphorylation of Akt at Thr308 and Ser473 as well as phosphorylation of BAD at 
Ser136 which are anti-apoptotic signals. Similar patterns were observed with all 
three cell lines, namely MCF-7, MDA-MB-231 and MCFIOA but the level of 
expression differed from each other. 
This study had provided three important information for researchers and clinicians in 
terms of: (1) evidence of the involvement of the SDF-la in the PI3WAkt signaling 
pathway in breast carcinoma tumourigenesis with detection of p-Akt. 2) For the first 
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time, we found cerbB2 was inversely correlated with SDF- 1 a expression. 3) 
Identification of potential targets for therapeutic intervention of breast carcinoma. 
On the basis of our data, we conclude that PI3WAkt signalling pathway is involved 
in tumorigenesis of breast cancer. To the best of our knowledge, this is the first 
report from Malaysia. PI3WAkt pathway might act with upstream molecules such as 
estradiol, SDF- 1 a, c-erbB2 independently in promoting tumour growth and 
inhibition of apoptosis. This study has also provided useful information for the 
search or design of antitumour interventions. 
Abstrak thesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai 
memenuhi keperluan untuk ijazah Master Sains 
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Barah payudara adalah barah yang paling biasa di Malaysia. Data dari segi genetik, 
eksperimen dan epidemiologi menunjukkan bahawa barah payudara berlaku apabila 
terdapat komunikasi yang kompleks antara faktor kejadian dan alam sekitar. 
Terdapat bukti yang mengatakan bahawa laluan isyarat PI3WAkt memain peranan 
dalarn kejadian barah payudara. 
Hubungan antara beberapa pengawal-atur atau biomolekul yang berkaitan dengan 
lintasan isyarat PI3WAkt telah dikaji dalam 43 tisu yang diperolehi daripada pesakit 
barah payudara dari tahun 1999 hingga 2002 telah diblokkan di dalam paraffin. 
Eksperimen fungsian telah dijalankan untuk menentukan ekspresi biomolekul Akt 
yang berhubungan dengan protin SDF-1 a. 
Keputusan kajian nenunjukkan bahawa: 1) ekspresi biomolekul ERa, ERP, c-erbB2, 
p-~ktT308, p- ~ k t ~ ~ ~ ,  p- ADS136, SDF-1 and Ki67 terdapat di tisu barah dalam 
peratus 25.6%, 4.7%, 51.2%, 81.4%, 48.8%, 67.4%, 93.0% and 26.8% masing- 
masing. Manakala ekspresi biomolekul tersebut pada tisu selkeliling yang kelihatan 
biasa adalah 23.1 %, 53.8%, 0%, 7.7%, 7.7%, 53.8%, 92.3% and 15.4% masing- 
masing. 2) Kolorasi biomolekul dengan tisu selkeliling yang kelihatan biasa adalah 
seperti berikut: ERP (p=0.001), c-erbB2 (p<0.001), p-AktT308 (p=<0.001) dan Ki67 
(p=<O.OOl). 3) Di tisu barah, kolerasi yang mencukupi terdapat di antara ERP dengan 
p-BAD (p=0.004), di antara p-AktS473 dengan pBAD (p=0.006), di antara c- 
erbB2 dengan p-~ktT308 dan Ki67 (p=0.014 dan p=0.000 masing-masing), di antara 
c-erbB2 dengan SDF-1 (p=0.047). Pada tisu selkeliling yang kelihatan biasa, 
kolerasi yang mencukupi terdapat di antara ERa dengan p-BAD (p=0.042), di 
antara ERP dengan p-Akt S473 dan p-BAD (p=0.009 dan p=0.001 masing-masing), 
di antara c-erbB2 dengan p - ~ k t  T308 (p=0.042). 
Kajian ini juga menunjukkan bahawa protin SDF-la menpunyai rangsangan yang 
berbeza terhadap exkpresi pelbagai biomolekul seperti p-~ktT308, p- ~ k t ~ ~ ~ ~  and p- 
BADS 136 . Dalarn kajian fhgs i  hi ,  karni mendapati SDF-la boleh merangsang 
kehidupan sel melalui penfosforilasi Akt pada Thr 308 dan Ser473 yang akan 
menfosforilasi BAD pada Ser136 dan lalu menutup laluan apoptotic. Terdapat 
kesamaan antara eksresi biomolekul pada tiga jenis sel yang lain, MCF-7, MDA- 
MB-23 1 dan MCFl OA dengan perbezaan tahap ekspresi yang berlainan. 
Kajian kami menghasilkan sekurang-kurangnya tiga maklumat yang penting kepada 
para penyelidik dan perubatan dari segi: 1) bukti pembabitan SDF-la dalam laluan 
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isyarat PI3WAkt dalam barah payudara. 2) Buat kali pertama, kami menunjukan 
bahawa c-erbB2 berkolerasi terbalik dengan ekspresi SDF-1. 3) Pengenalan sasaran- 
potensi bagi intervensi barah payudara terapi maju. Berdasarkan keputusan int, karni 
mencadangkan bahawa SDF-la boleh dianggap sebagai sasaran terapeutik yang 
berpotensi untuk rawatan immuno barah payudara. 
Berdasarkan keputusan yang diperolehi, kami membuat kesimpulan bahawa lintasan 
isyarat PI3WAkt adalah berkait dengan tumorigenesis barah payudara di Malaysia. 
Lintasan isyarat ini adalah saling berhubungan dengan molekul awalan seperti 
estradiol, SDF-la dan c-erbB2 walaupun mereka juga boleh bertindak secara 
berasingan untuk menggalakkan pertumbuhan barah dan perencatan apoptosis. 
Kajian ini telah memberi maklumat yang berguna kepada para penyelidik dan 
perubatan dalam penemuan dan perekaan cara anti-barah yang lebih baik. 
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CHAPTER 1 
INTRODUCTION 
Cancer is a disease that involves the dysfunction of the immune system. 
Transformation of normal cells to abnormal cells usually leads to apoptosis of that 
transformed cells. Cancer occurs when the immune system lost its ability to do 
surveillance to destroy those abnormal cells. The cancer cells could then proliferate 
uncontrollably into a mass. Loss of their normal fbnction may interfere with the other 
body systems. 
Breast cancer is the commonest cancer among women all around the world and it is a 
significant global disease burden. In Malaysia, there were 4337 cases reported by the 
National Cancer Registry Malaysia 2002. Worldwide, the ratio of mortality to 
incidence is about 36% which, compared to other cancer types, represents a 
relatively good prognosis. However, it remains the leading cause of cancer mortality 
in women and its treatment is often associated with toxicity and unfavourable 
cosmetic outcome that impacts greatly on quality of life. 
After several decades of cancer research focusing only on the tumour cell itself, we 
are just realizing that cancer is not only a group of abnormally growing cells, but it is 
an abnormal mass with multiple cell types communicating with each other (Polyak, 
2001). 
Many methods of early detection and treatment of breast cancer had been developed, 
but they are still not enough to fully and successfully treat all breast cancer patients. 
Intensive research efforts have been conducted to find the cause of this disease, but 
unfortunately, the causative factor of the disease has still not been found. 
Oestrogen receptor a (ERa) belongs to the superfamily of steroid nuclear receptor 
transcriptional factors. It regulates the proliferation and differentiation of many 
tissues, especially reproductive tissues. On binding to specific DNA sequences such 
as estrogen responsive elements (EREs), oestrogen-ERa complexes activate or 
repress target gene transcription. The biological activity of oestrogen is now realized 
to be more complex than initially thought, with the discovery of a second oestrogen 
receptor (ER) named ERP (Girault et al., 2003). ERs utilize the membrane epidermal 
growth factor receptor (EGFR) to rapidly signal through various kinase cascades that 
influence both transcriptional and non-transcriptional actions of estrogen in breast 
cancer cells (Levin et al., 2003). Recent evidence suggests that common adaptations 
which occur during resistance to both tamoxifen and oestrogen deprivation use 
various signal transduction pathways, often involving cross-talk with a retained and 
functional ER protein (Johnston et al., 2003). Oh and colleagues (2001) found that 
hyperactivation of mitogen-activated protein kinase (MAPK) could induce loss of 
ERa expression in breast cancer cells. This might be one of the causes of resistance 
to antioestrogen drugs in ERa positive cells. Studies of forced c-erbB2 
overexpression in animals and cell lines have demonstrated the oncogenic potential 
of c-erbB2, and spontaneous homodimerization leading to tyrosine kinase activation 
is most likely an important mechanism for the oncogenicity of c-erbB2 
overexpression (Siege1 and Muller, 1996). Lindberg and colleagues identified the 
